Cardinal Health stock gains on strong fiscal 2026 earnings outlook

Cardinal Health, Inc. stock (ISIN US14149Y1082) ended the last completed trading day on the New York Stock Exchange at USD 224.95 on September 18, 2026, leaving upside of about 18.5 percent to the average analyst price target of USD 266.56 based on current consensus data.

Fiscal 2026 earnings trajectory underpins valuation

Management is emphasizing earnings growth as the key driver for Cardinal Health’s valuation in the current fiscal year and beyond. According to Yahoo Finance in an analysis dated September 19, 2026, Cardinal Health reported that all five operating segments delivered double-digit earnings growth in fiscal 2026, providing a strong base for future performance.

In the same coverage, management noted that fiscal 2026 benefited from unusually strong specialty growth, customer onboarding, acquisitions and solid healthcare utilization, and expects growth to normalize in fiscal 2027 as these tailwinds moderate.Yahoo Finance For investors, this shift means the emphasis moves from one-off boosts to sustainable earnings expansion.

EPS growth target and segment performance

Beyond the reported results, Cardinal Health has set an ambitious medium-term earnings goal. According to a separate analysis by Yahoo Finance on September 19, 2026, the company is targeting adjusted earnings per share growth of 13 to 15 percent per year starting from fiscal 2026, supported by its diversified healthcare services and products portfolio.

The same report highlights that all five operating segments achieved double-digit earnings growth in fiscal 2026, which suggests a broad-based improvement rather than reliance on a single business line.Yahoo Finance While exact earnings figures per segment were not detailed in the snippets, the double-digit growth statement establishes a quantified comparison versus prior-year performance and underpins the EPS growth target.

Analyst consensus and upside potential

Analyst sentiment toward Cardinal Health remains constructive. A current overview from MarketBeat as of September 19, 2026 describes the stock as having a consensus rating of Moderate Buy, based on an average rating score of 2.84 from 16 buy ratings and 3 hold ratings.

The same MarketBeat data set an average price target for Cardinal Health at USD 266.56, implying upside of about 18.5 percent from the closing price of USD 224.95 on September 18, 2026.MarketBeat For investors, this quantified gap between the market price and the consensus target reflects the expectation that the company’s earnings trajectory can support further share gains, even after the recent run.

MarketBeat also notes that Cardinal Health’s shares were trading at USD 205.62 at the beginning of the year 2026 and have since increased by 9.4 percent to USD 224.95 as of September 18, 2026.MarketBeat This year-to-date performance provides historical context for the current valuation but does not on its own determine future returns.

Stock valuation and trading metrics

From a market-data perspective, Cardinal Health’s share price sits within a wide 52-week trading range. Per MarketBeat, the stock’s 52-week low stands at USD 145.87 and the 52-week high at USD 258.30, with the as-of state tied to the same data snapshot that recorded the USD 224.95 closing price on September 18, 2026.MarketBeat At this level the shares trade closer to the upper end of their 52-week range but still below the high, suggesting that the rally has been significant yet not exhaustive.

In the same overview, MarketBeat reports a market capitalization of USD 52.32 billion for Cardinal Health as of the latest price snapshot, based on the USD 224.95 share price.MarketBeat The trailing price-to-earnings ratio is indicated at 31.11, which places the stock in a valuation zone that reflects growth expectations rather than deep value characteristics.

MarketBeat further notes that Cardinal Health’s dividend yield stands at 0.92 percent based on current payout and price levels, a relatively modest cash return compared with some higher-yielding healthcare peers.MarketBeat For income-focused investors, this means the investment case is driven more by potential capital gains tied to EPS growth and less by dividend income.

Risk factors around normalization of growth

The key risk in Cardinal Health’s current story lies in the expected normalization of growth after an unusually strong fiscal 2026. As Yahoo Finance reports, fiscal 2026 earnings were boosted by exceptional specialty growth, customer onboarding, acquisitions and robust healthcare utilization, and management expects these contributions to moderate in fiscal 2027.

If specialty volumes, onboarding momentum or acquisition-related synergies fall back faster than anticipated, the targeted adjusted EPS growth of 13 to 15 percent per year from fiscal 2026 could be more difficult to achieve.Yahoo Finance For investors, this introduces a sensitivity of the valuation to any signs that growth is normalizing faster or to a lower base than the market currently discounts.

Current stock level for investors

Cardinal Health stock closed at USD 224.95 on the New York Stock Exchange as of September 18, 2026, down 0.61 percent from the prior close according to MarketBeat’s price snapshot, with an extended-hours indication of USD 225.92 later that day.MarketBeat This places the shares roughly midway between the year’s starting level of USD 205.62 and the 52-week high of USD 258.30, while still below the consensus price target of USD 266.56.

More news and analyses on Cardinal Health stock